Evolution of TALENs
Engineered transcriptional activator-like effectors (TALEs) are versatile tools for genome manipulation with applications in research and clinical contexts. One current drawback of TALEs is that the 5′ nucleotide of the target is specific for thymine (T). TALE domains with alternative 5′ nucleotide specificities could expand the scope of DNA target sequences that can be bound by TALEs. Another drawback of TALEs is their tendency to bind and cleave off-target sequence, which hampers their clinical application and renders applications requiring high-fidelity binding unfeasible. This disclosure provides methods and strategies for the continuous evolution of proteins comprising DNA-binding domains, e.g., TALE domains. In some aspects, this disclosure provides methods and strategies for evolving such proteins under positive selection for a desired DNA-binding activity and/or under negative selection against one or more undesired (e.g., off-target) DNA-binding activities. Some aspects of this disclosure provide engineered TALE domains and TALEs comprising such engineered domains, e.g., TALE nucleases (TALENs), TALE transcriptional activators, TALE transcriptional repressors, and TALE epigenetic modification enzymes, with altered 5′ nucleotide specificities of target sequences. Engineered TALEs that target ATM with greater specificity are also provided.
1. A protein comprising a transcriptional activator-like effector (TALE) N-terminal domain having the amino acid sequence set forth in SEQ ID NO: 1, wherein the amino acid sequence comprises an alanine to glutamic acid amino acid substitution at amino acid residue 39 of SEQ ID NO: 1, wherein the protein has DNA-binding activity.
2. The protein of claim 1 further comprising a lysine to glutamic acid substitution at amino acid residue 19 of SEQ ID NO: 1.
3. The protein of claim 1 further comprising a glycine to arginine amino acid substitution at amino acid residue 98 of SEQ ID NO: 1.
4. A protein comprising a TALE N-terminal domain having the amino acid sequence set forth in SEQ ID NO: 1, wherein the amino acid sequence comprises a lysine to glutamic acid substitution at amino acid residue 19 of SEQ ID NO: 1, wherein the protein has DNA-binding activity.
5. The protein of claim 4 further comprising a glycine to arginine amino acid substitution at amino acid residue 98 of SEQ ID NO: 1.
6. The protein of claim 1 further comprising one or more amino acid substitutions selected from the group consisting of S22N, G77D, A85T, T91A, A93G, P99S, P99T, A129E, and N136T of SEQ ID NO: 1.
7. The protein of claim 1 further comprising an arginine to tryptophan amino acid substitution at amino acid residue 21 of SEQ ID NO: 1.
8. The protein of claim 4 further comprising one or more amino acid substitutions selected from the group consisting of S22N, G77D, A85T, T91A, A93G, P99S, P99T, A129E, and N136T of SEQ ID NO: 1.
9. The protein of claim 4 further comprising an arginine to tryptophan amino acid substitution at amino acid residue 21 of SEQ ID NO: 1.
10. A method comprising contacting a nucleic acid molecule comprising a target sequence with the protein of claim 1 under conditions suitable for the protein to bind the target sequence.
11. The method of claim 10 , wherein the contacting is in vitro.
12. The method of claim 10 , wherein the contacting is in vivo.
13. The method of claim 10 , wherein the nucleic acid molecule is in a cell.
14. The method of claim 13 , wherein the cell is a mammalian cell.
15. A method comprising contacting a nucleic acid molecule comprising a target sequence with the protein of claim 4 under conditions suitable for the protein to bind the target sequence.
16. The method of claim 15 , wherein the contacting is in vitro.
17. The method of claim 15 , wherein the contacting is in vivo.
18. The method of claim 15 , wherein the nucleic acid molecule is in a cell.
19. The method of claim 18 , wherein the cell is a mammalian cell.